| Company: | Abbott Laboratories |
|---|---|
| CEO: |
|
| Founded: | 1888 |
| Symbol: | ABT |
| Exchange: | NYSE |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| About |
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions,luding pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. Theselude laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois. |
10 among 2804 companies
100 Abbott Park Road
Abbott Park | IL |
US
| Abbott Laboratories;ABT;https://bullfincher.io/logos/us/ABT.png;abbott-laboratories | 44328000000.00 |
|---|---|
| Stryker Corporation;SYK;https://bullfincher.io/logos/us/SYK.png;stryker-corporation | 25116000000.00 |
| Boston Scientific Corporation;BSX;https://bullfincher.io/logos/us/BSX.png;boston-scientific-corporation | 20074000000.00 |
| DexCom;DXCM;https://bullfincher.io/logos/us/DXCM.png;dexcom | 4662000000.00 |
Abbott Laboratories was founded on 1888, which makes the company 138 years old.
Robert Ford is the CEO of Abbott Laboratories.
Abbott Laboratories operates in the Medical - Devices industry and the Healthcare sector.
Abbott Laboratories has 115,000 employees.
In fiscal year 2025, Abbott Laboratories generated a revenue of $44.33 Billion.
In fiscal year 2025, Abbott Laboratories reported a net income of $6.52 Billion.
Medical Devices is Abbott Laboratories's biggest product segment, representing 48.27% of its total revenue.
Abbott Laboratories went public on Mar 17, 1980, through its Initial Public Offering (IPO), and it has been 46 years since then.
Abbott Laboratories's ticker symbol is ABT, and the company is listed on the NYSE stock market exchange.
Abbott Laboratories's current stock price is $92.12 as of Jul 14, 2026.
Ranked #10among 2,804 companies based on market cap.
Competitors of Abbott Laboratories include Stryker Corporation, Boston Scientific Corporation and DexCom, and more.